Eli Lilly & Co., which has sued the Canadian government for $500 million, has filed a legal document with the international trade body that will decide the case, charging that Canada violated international law when it invalidated two of its key patents.
The company said the invalidation by Canadian courts of patents for two Lilly drugs—Zyprexa, used in the treatment of schizophrenia; and Strattera, used to treat Attention Deficit Hyperactivity Disorder (ADHD)—is illegal and “constitutes an uncompensated expropriation,” according to the memorial it filed with the U.N. Commission on International Trade Law and the North American Free Trade Agreement.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
